CyberHeart secures $9M in financing to further collaborate with Accuray
CyberHeart, a medical device company developing a non-invasive system to treat cardiac arrhythmias, has closed a $9 million Series A financing.
The investment was co-led by Emergent Medical Ventures of Portola Valley, Calif., and United Investments of Taipei, Taiwan. Also participating in the round were Venture Select of Munich, Germany, and Mitsubishi of New York City.
The Menlo Park, Calif-based CyberHeart said it plans to use the financing to fund the development of proprietary non-invasive technology for cardiac applications using the CyberKnife System from Accuray of Sunnyvale, Calif. The CyberKnife System is a robotic radiosurgery system, which tracks, detects and corrects for motion throughout the treatment, according to CyberHeart.
The company, with the cooperation of Accuray, said it is developing hardware and software modifications that would extend the therapy to cardiac applications.
The investment was co-led by Emergent Medical Ventures of Portola Valley, Calif., and United Investments of Taipei, Taiwan. Also participating in the round were Venture Select of Munich, Germany, and Mitsubishi of New York City.
The Menlo Park, Calif-based CyberHeart said it plans to use the financing to fund the development of proprietary non-invasive technology for cardiac applications using the CyberKnife System from Accuray of Sunnyvale, Calif. The CyberKnife System is a robotic radiosurgery system, which tracks, detects and corrects for motion throughout the treatment, according to CyberHeart.
The company, with the cooperation of Accuray, said it is developing hardware and software modifications that would extend the therapy to cardiac applications.